Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
about
Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysisNomogram to predict rectal toxicity following prostate cancer radiotherapy.The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups.Hypofractionated radiotherapy for localized prostate cancer.Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.Rectal protection in prostate stereotactic radiotherapy: a retrospective exploratory analysis of two rectal displacement devices.Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.Exploiting Gene Expression Kinetics in Conventional Radiotherapy, Hyperfractionation, and Hypofractionation for Targeted Therapy.Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer.Cyberknife Radioablation of Prostate Cancer – Preliminary Results for 400 PatientsReducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives.Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results.Hypofractionation trials and radiobiology of prostate cancer.Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination.Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial.Moderate hypofractionation for prostate cancer.Challenges in the Analysis of Outcomes for Surgical Compared to Radiotherapy Treatment of Prostate Cancer.Updates on the diagnosis and treatment of prostate cancer.Moderate hypofractionation for prostate cancer: A user's guide.Predictors of acute urinary symptom flare following stereotactic body radiation therapy (SBRT) in the definitive treatment of localized prostate cancer.Prostate cancer: Moderate hypofractionated radiotherapy - not yet a standard of care.Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn't!Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer.Dosimetric Implications of Computerised Tomography-Only versus Magnetic Resonance-Fusion Contouring in Stereotactic Body Radiotherapy for Prostate Cancer.Reducing errors in prostate tracking with an improved fiducial implantation protocol for CyberKnife based stereotactic body radiotherapy (SBRT).A Younger Man With Localized Prostate Cancer Asks, "Which Type of Radiation Is Right for Me?"Moderate hypofractionation for prostate cancerIntensity-modulated radiotherapy for prostate cancerONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trialHypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes
P2860
Q36214859-58C02381-9511-4F5C-9975-8F12D16747C8Q36412497-73D3D770-C1DD-4CF5-B5A3-A96BF1CB67B9Q37195789-6D933345-8A84-4D0B-BB31-357F483D2C35Q37547386-F7E03959-4279-4028-9DE1-108807313417Q37578562-FA469296-41C8-4BCC-8AEA-806E20FCAFD7Q37586877-13E4B8C7-0B88-4B98-BDFC-80B2831A3481Q38635368-710329A3-AE61-458F-AFBC-EECB68EA53D4Q38640272-032FC19F-1F91-4CC9-AE9F-D604928F0637Q38952268-67FAB471-6D55-4084-B0DE-E3967DCBBA7EQ39313355-60F1291B-A885-47FE-90CC-C34015FD8C31Q40982235-40143605-4002-49B0-B0F2-4EE67B902E89Q41276603-DDC5344A-2B07-4515-B173-25406A205D2EQ41872926-AC9F753D-EBB4-4E73-A9E0-10C8261C8B16Q42347543-8178D281-FE72-4750-B67F-EF795BA448E2Q42380315-7CAA4FE3-CA39-44EF-83FF-5CCCD074B921Q43379657-119A8882-D305-4E0E-9CA9-08E0BFE76C83Q47155360-5615792C-8283-44E6-9D5A-BED3EF2DA77EQ47185878-C593B431-F6D6-4C65-A228-110FCB5AD87AQ47361793-DCE00F4A-99C5-48AE-8CA7-B6554BAA4FF3Q48238146-97ED9150-3E3E-49EE-898B-80DF542A9AECQ54358254-A3A1D700-0193-4636-B6EC-EA5090D64B63Q54640902-B027239A-8340-4E15-A214-9DD858634BC3Q55038620-26F8E433-E8F4-41D4-9D4F-786F0B49FBCBQ55100642-EBAC00A2-50AE-4E85-9DFC-2D003FA250DEQ55425041-F0E92F10-A277-47B1-9B35-49761B1A85F3Q55501070-926D7AF2-6473-42EB-89BD-F6FCEF94E110Q57111203-45F83DCB-DD66-42F1-B6ED-D0CC98AAD07BQ57112499-5DAE3F2A-89FB-4376-93CC-F87E775C6266Q57112525-61CA5D55-098F-4906-B60B-D9BEA581095CQ58765203-741C150A-FC4D-496E-BB4E-BCB697EF5968Q59126113-1F389507-FF6D-48F7-84F3-0B5EAA0EBEB0
P2860
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Randomized Phase III Noninferi ...... With Low-Risk Prostate Cancer.
@ast
Randomized Phase III Noninferi ...... With Low-Risk Prostate Cancer.
@en
type
label
Randomized Phase III Noninferi ...... With Low-Risk Prostate Cancer.
@ast
Randomized Phase III Noninferi ...... With Low-Risk Prostate Cancer.
@en
prefLabel
Randomized Phase III Noninferi ...... With Low-Risk Prostate Cancer.
@ast
Randomized Phase III Noninferi ...... With Low-Risk Prostate Cancer.
@en
P2093
P2860
P356
P1476
Randomized Phase III Noninferi ...... With Low-Risk Prostate Cancer.
@en
P2093
Amit B Shah
Bridget F Koontz
Daniel Low
David P D'Souza
Deborah W Bruner
Gregory P Swanson
Howard M Sandler
Ian S Dayes
James J Dignam
Jeff M Michalski
P2860
P304
P356
10.1200/JCO.2016.67.0448
P407
P577
2016-04-04T00:00:00Z